Equities analysts forecast that Hologic, Inc. (NASDAQ:HOLX) will announce sales of $782.88 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Hologic’s earnings, with estimates ranging from $780.40 million to $784.30 million. Hologic posted sales of $734.40 million during the same quarter last year, which would suggest a positive year over year growth rate of 6.6%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, February 7th.

On average, analysts expect that Hologic will report full-year sales of $782.88 million for the current fiscal year, with estimates ranging from $3.23 billion to $3.34 billion. For the next financial year, analysts anticipate that the business will report sales of $3.41 billion per share, with estimates ranging from $3.37 billion to $3.45 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Hologic.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The company had revenue of $802.90 million for the quarter, compared to analysts’ expectations of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The business’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Several brokerages have recently issued reports on HOLX. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $45.00 target price (down from $50.00) on shares of Hologic in a report on Wednesday, August 9th. Barclays PLC reiterated an “equal weight” rating and issued a $51.00 target price (down from $53.00) on shares of Hologic in a report on Wednesday, August 9th. Piper Jaffray Companies reiterated a “buy” rating and issued a $48.00 target price on shares of Hologic in a report on Thursday, November 9th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $47.54.

In other Hologic news, Director Lawrence M. Levy sold 7,139 shares of Hologic stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total value of $278,706.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 7,138 shares of Hologic stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,949 shares of company stock valued at $1,345,220. 0.79% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of HOLX. Parnassus Investments CA acquired a new stake in Hologic in the third quarter valued at approximately $277,062,000. Capital World Investors acquired a new stake in Hologic in the second quarter valued at approximately $312,441,000. HealthCor Management L.P. acquired a new stake in Hologic in the second quarter valued at approximately $76,604,000. Columbus Circle Investors acquired a new stake in Hologic in the second quarter valued at approximately $54,511,000. Finally, Vanguard Group Inc. lifted its stake in Hologic by 4.2% in the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after acquiring an additional 1,200,825 shares during the last quarter. Hedge funds and other institutional investors own 96.41% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/17/782-88-million-in-sales-expected-for-hologic-inc-holx-this-quarter.html.

Shares of Hologic (NASDAQ:HOLX) traded up $0.47 on Friday, hitting $39.72. 1,472,600 shares of the stock traded hands, compared to its average volume of 2,742,896. The firm has a market cap of $11,314.73, a PE ratio of 19.43, a P/E/G ratio of 1.90 and a beta of 0.93. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.79 and a quick ratio of 0.61. Hologic has a 12 month low of $35.76 and a 12 month high of $46.80.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.